

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(MBHB Case No. 03-1070 (400.139))



In re Application of:)	
)	
McSwiggen et al.)	
)	
Serial No.: 10/727,780)	Group Art Unit: 1645
)	
Filed: December 3, 2003)	Examiner: Not Assigned
)	
For: Inhibition of Gene Expression Using)	Confirmation No.: 7111
Duplex Forming Oligonucleotides)	

REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop OIPE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attention: Office of Initial Patent Examination's
Filing Receipt Corrections

1. Attached is a copy of the filing receipt received from the PTO in the above-referenced application for which issuance of a new filing receipt is respectfully requested.

2. There is an error with respect to the following data, which is incorrectly entered.
Error in
Domestic Priority data as claimed by applicant:

Please insert -- This application is a continuation-in-part of U.S. Patent Application No. 10/757,803, filed January 14, 2004, which is a continuation-in-part of U.S. Patent Application No. 10/720,448, filed November 24, 2003, which is a continuation-in-part of U.S. Patent Application No. 10/693,059, filed October

23, 2003, which is a continuation-in-part of U.S. Patent Application No. 10/444,853, filed May 23, 2003, which is a continuation-in-part of International Patent Application No. PCT/US03/05346, filed February 20, 2003, and a continuation-in-part of International Patent Application No. PCT/US03/05028, filed February 20, 2003, both of which claim the benefit of U.S. Provisional Application No. 60/358,580 filed February 20, 2002, U.S. Provisional Application No. 60/363,124 filed March 11, 2002, U.S. Provisional Application No. 60/386,782 filed June 6, 2002, U.S. Provisional Application No. 60/406,784 filed August 29, 2002, U.S. Provisional Application No. 60/408,378 filed September 5, 2002, U.S. Provisional Application No. 60/409,293 filed September 9, 2002, and U.S. Provisional Application No. 60/440,129 filed January 15, 2003.


3. The correction is not due to any error by applicant and no fee is due.

Respectfully submitted,

McDonnell, Boehnen, Hulbert & Berghoff

Date: October 4, 2004

By: _____


Christopher P. Singer
Registration No. 48,701



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/727,780	12/03/2003	1645	403	MBHB03-1070 (400/139)	13	22	1

CONFIRMATION NO. 7111

020306
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 S. WACKER DRIVE
32ND FLOOR
CHICAGO, IL 60606

FILING RECEIPT



OC000000013418597

Date Mailed: 08/03/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

James McSwiggen, Boulder, CO;
Narendra K. Vaish, Denver, CO;
Shawn Zinnen, Denver, CO;

DOCKETED

AUG 09 2004

IDS-3103/04
DUE DATE 10/03/04
BY LPIC

Assignment For Published Patent Application

Sirna Therapeutics, Inc., Boulder, CO;

Domestic Priority data as claimed by applicant

Foreign Applications

UNITED STATES OF AMERICA PCT/US03/05346 02/20/2003

UNITED STATES OF AMERICA PCT/US03/05028 02/20/2003

If Required, Foreign Filing License Granted: 08/02/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

*This application is a CIP of 10/757,803 1.14.04
which is a CIP of 10/720,448 11.24.03
which is a CIP of 10/693,059 10.23.03
which is a CIP of 10/444,853 05.23.03
and a CIP of PCT/US03/05346 02.20.03
and a CIP of PCT/US03/05028 02.20.03
and said PCT applications
PCT/US03/05346 and PCT/US03/05028
claim the benefit of
60/358,580 02.20.20
and said PCT Applications PCT/US03/05346 and
PCT/US03/05028 claim the benefit of 60/363,124 3.11.02
and said PCT Applications PCT/US03/05346 and
PCT/US03/05028 claim the benefit of 60/386,782 06.06.02
and said PCT Applications PCT/US03/05346 and PCT/US03/05028
claim the benefit of 60/406,784 08.29.02
and said PCT Applications PCT/US03/05346 and PCT/US03/05028
claim the benefit of 60/408,378 09.05.02
and said PCT Applications PCT/US03/05346 and PCT/US03/05028
claim the benefit of 60/409,293 09.09.02 (COVER)*

Title

Inhibition of gene expression using duplex forming oligonucleotides

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Continued:

and said PCT applications PCT/us03/05346 and PCT/us03/05028
claim the benefit of 60/440,129 01.15.03